In Vitro Terbinafine Susceptibility of Dermatophytes and Mycological Cure Outcomes from a Multicenter Phase III Onychomycosis Trial

Background

Dermatophyte infections, including onychomycosis, affect millions worldwide. Terbinafine, an allylamine antifungal, remains a foundational method of treatment.

Objective

We aim to evaluate the in vitro antifungal susceptibility of terbinafine against dermatophyte isolates obtained from patients participating in a Phase III onychomycosis clinical trial.

Methods